Switching off autoimmunity.

The article focuses on the development and clinical success of CD40L antagonists for treating autoimmune diseases. Topics include the pivotal role of CD40L in immune responses and inflammation, the progress of CD40L antagonists in clinical trials for diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS), and the emergence of next-generation CD40L blockers with improved safety profiles and therapeutic efficacy.